Response criteria in solid tumors (PERCIST/RECIST) and SUVmax in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1748-717X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Response criteria in solid tumors (PERCIST/RECIST) and SUVmax in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy ; volume:13 ; number:1 ; day:27 ; month:2 ; year:2018 ; pages:1-9 ; date:12.2018
Radiation oncology ; 13, Heft 1 (27.2.2018), 1-9, 12.2018
- Urheber
-
Pierson, Cory
- Beteiligte Personen und Organisationen
-
Grinchak, Taras
Sokolovic, Casey
Holland, Brandi
Parent, Teresa
Bowling, Mark
Arastu, Hyder
Walker, Paul
Ju, Andrew
SpringerLink (Online service)
- DOI
-
10.1186/s13014-018-0980-7
- URN
-
urn:nbn:de:1111-201804241314
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Pierson, Cory
- Grinchak, Taras
- Sokolovic, Casey
- Holland, Brandi
- Parent, Teresa
- Bowling, Mark
- Arastu, Hyder
- Walker, Paul
- Ju, Andrew
- SpringerLink (Online service)
Ähnliche Objekte (12)
Cost-effectiveness of stereotactic body radiotherapy versus conventional fractionated radiotherapy for medically inoperable, early-stage non-small cell lung cancer
Stereotactic body radiotherapy for early-stage non-small cell lung cancer: clinical outcomes from a National Patient Registry
Systemic immune modulation by stereotactic radiotherapy in early-stage lung cancer
Systemic immune modulation by stereotactic radiotherapy in early-stage lung cancer
Stereotactic ablative radiotherapy for early-stage lung cancer following double lung transplantation
Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch® patient registry
Systematic review of economic evaluations on stereotactic ablative radiotherapy (SABR) compared to other radiotherapy techniques or surgical procedures for early-stage non-small cell lung cancer
Multi-omics integrative modelling for stereotactic body radiotherapy in early-stage non-small cell lung cancer: clinical trial protocol of the MONDRIAN study
Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial
Long-term survival and failure patterns in inoperable early-stage non-small cell lung cancer following stereotactic body radiotherapy: a single-institution retrospective study
Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer
Dose–effect relationship of stereotactic body radiotherapy in non-small cell lung cancer patients
Cost-effectiveness of stereotactic body radiotherapy versus conventional fractionated radiotherapy for medically inoperable, early-stage non-small cell lung cancer
Stereotactic body radiotherapy for early-stage non-small cell lung cancer: clinical outcomes from a National Patient Registry
Systemic immune modulation by stereotactic radiotherapy in early-stage lung cancer
Systemic immune modulation by stereotactic radiotherapy in early-stage lung cancer
Stereotactic ablative radiotherapy for early-stage lung cancer following double lung transplantation
Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch® patient registry
Systematic review of economic evaluations on stereotactic ablative radiotherapy (SABR) compared to other radiotherapy techniques or surgical procedures for early-stage non-small cell lung cancer
Multi-omics integrative modelling for stereotactic body radiotherapy in early-stage non-small cell lung cancer: clinical trial protocol of the MONDRIAN study
Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial
Long-term survival and failure patterns in inoperable early-stage non-small cell lung cancer following stereotactic body radiotherapy: a single-institution retrospective study
Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer
Dose–effect relationship of stereotactic body radiotherapy in non-small cell lung cancer patients
Cost-effectiveness of stereotactic body radiotherapy versus conventional fractionated radiotherapy for medically inoperable, early-stage non-small cell lung cancer
Stereotactic body radiotherapy for early-stage non-small cell lung cancer: clinical outcomes from a National Patient Registry
Systemic immune modulation by stereotactic radiotherapy in early-stage lung cancer
Systemic immune modulation by stereotactic radiotherapy in early-stage lung cancer
Stereotactic ablative radiotherapy for early-stage lung cancer following double lung transplantation
Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch® patient registry
Systematic review of economic evaluations on stereotactic ablative radiotherapy (SABR) compared to other radiotherapy techniques or surgical procedures for early-stage non-small cell lung cancer
Multi-omics integrative modelling for stereotactic body radiotherapy in early-stage non-small cell lung cancer: clinical trial protocol of the MONDRIAN study
Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial
Long-term survival and failure patterns in inoperable early-stage non-small cell lung cancer following stereotactic body radiotherapy: a single-institution retrospective study
Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer